MMAF intermediate 1

• CAT Number: I040441
• CAS Number: 161485-82-1
• Molecular Formula: C24H36N2O6
• Molecular Weight: 448.55
• Purity: ≥95%
• Synonyms: tert-butyl (2S)-2-[(1R,2R)-1-methoxy-3-[[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-oxopropyl]pyrrolidine-1-carboxylate
• InChI: InChI=1S/C24H36N2O6/c1-16(20(30-5)19-13-10-14-26(19)23(29)32-24(2,3)4)21(27)25-18(22(28)31-6)15-17-11-8-7-9-12-17/h7-9,11-12,16,18-20H,10,13-15H2,1-6H3,(H,25,27)/t16-,18+,19+,20-/m1/s1
• InChIKey: RDNYSJATGQDZQN-BTHPGYMESA-N
• SMILES: CC(C(C1CCCN1C(=O)OC(C)(C)C)OC)C(=O)NC(CC2=CC=CC=C2)C(=O)OC

MMAF Intermediate 1(CAT: I040441) is an essential building block in the synthesis of Monomethyl Auristatin F (MMAF, HY-15579), a highly potent antimitotic agent widely employed as the cytotoxic payload in antibody-drug conjugates (ADCs). MMAF exerts its therapeutic effect by inhibiting tubulin polymerization, resulting in mitotic arrest and apoptosis in rapidly dividing cancer cells. It serves as the active component in clinically relevant ADCs such as Vorsetuzumab mafodotin and SGN-CD19A. MMAF Intermediate 1 supports the stepwise and scalable construction of the final MMAF molecule, making it indispensable for ADC payload development, cytotoxic conjugate research, and targeted oncology drug manufacturing.